{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-045673","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.375288+00:00","generated_at":"2026-05-25T15:40:43.889539+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"confidence":"high","headline":"IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026","bullets":["Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.","Cash and equivalents ~$60M as of Dec 31, 2024; secured up to €57.5M EIB debt, extending runway into Q2 2026.","Phase 2 basket trial (resectable melanoma/SCCHN) enrollment completed at 95 patients; initial data expected H2 2025.","Phase 2 IOB-022 met primary endpoint ORR in SCCHN; promising PFS in SCCHN and NSCLC; longer-term data H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-045673","json":"https://secwatch.observer/filing/0001193125-25-045673.json","markdown":"https://secwatch.observer/filing/0001193125-25-045673.md","text":"https://secwatch.observer/filing/0001193125-25-045673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525045673/0001193125-25-045673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525045673/d924521d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T15:40:43.889539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}